- Home
- EBS vs XOMA Comparison
EBS vs XOMA Comparison
Compare EBS & XOMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EBS
- XOMA
- Stock Information
- Founded
- EBS 1998
- XOMA 1981
- Country
- EBS United States
- XOMA United States
- Employees
- EBS N/A
- XOMA N/A
- Industry
- EBS Biotechnology: Pharmaceutical Preparations
- XOMA Biotechnology: Pharmaceutical Preparations
- Sector
- EBS Health Care
- XOMA Health Care
- Exchange
- EBS Nasdaq
- XOMA Nasdaq
- Market Cap
- EBS 529.9M
- XOMA 457.6M
- IPO Year
- EBS 2006
- XOMA N/A
- Fundamental
- Price
- EBS $10.93
- XOMA $31.86
- Analyst Decision
- EBS Strong Buy
- XOMA Strong Buy
- Analyst Count
- EBS 1
- XOMA 2
- Target Price
- EBS $15.00
- XOMA $69.50
- AVG Volume (30 Days)
- EBS 1.5M
- XOMA 53.3K
- Earning Date
- EBS 10-29-2025
- XOMA 11-12-2025
- Dividend Yield
- EBS N/A
- XOMA N/A
- EPS Growth
- EBS N/A
- XOMA N/A
- EPS
- EBS 1.35
- XOMA 0.82
- Revenue
- EBS $788,900,000.00
- XOMA $47,106,000.00
- Revenue This Year
- EBS N/A
- XOMA $88.91
- Revenue Next Year
- EBS $15.42
- XOMA $13.80
- P/E Ratio
- EBS $8.11
- XOMA $38.70
- Revenue Growth
- EBS N/A
- XOMA 118.02
- 52 Week Low
- EBS $4.02
- XOMA $18.35
- 52 Week High
- EBS $13.41
- XOMA $39.92
- Technical
- Relative Strength Index (RSI)
- EBS 57.23
- XOMA 40.37
- Support Level
- EBS $9.02
- XOMA $31.26
- Resistance Level
- EBS $10.29
- XOMA $34.11
- Average True Range (ATR)
- EBS 0.58
- XOMA 1.62
- MACD
- EBS -0.03
- XOMA -0.07
- Stochastic Oscillator
- EBS 93.69
- XOMA 15.43
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.
About XOMA XOMA Corporation
XOMA Royalty Corp is a biotechnology royalty aggregator playing a role in helping biotech companies achieve their goal of improving human health. XOMA acquires the potential future economics associated with pre-commercial therapeutic candidates that have been licensed to pharmaceuticals or biotechnology companies. XOMA acquires future economic rights, the seller receives non-dilutive, non-recourse funding that can use to advance their internal drug candidate(s) or for general corporate purposes. Geographically, the company operates in Switzerland, United States, Asia Pacific, Europe and Others.